Dune Medical Devices said last week that it promoted medical device veteran Lori Chmura to be its new CEO, replacing founder and former chief Dan Hashimshony.
“This is a natural evolution for a growth-stage device company which will enable me to focus more intensely on expansion of our proprietary radiofrequency spectroscopy platform into new devices and oncology markets,” Hashimshony said in prepared remarks. “I am looking forward to continuing to work with Lori and the team at Dune on a set of strategic initiatives to extend the application of Dune’s technology beyond breast cancer surgery.”
“I am humbled by the opportunity and the confidence that Dan and the board have entrusted to me as Dune enters its next stage in commercialization,” Chmura added. “The team’s commitment to quality, passion, excellence and execution will not waiver. We will continue to uphold the company’s foundation and work tirelessly to ensure that we achieve the success within our collective reach.
“We put unique clinically actionable information into the hands of surgeons while in the OR to help them make the best possible decisions for patient care,” she said. “Improving the standard of care around cancer surgery is what we strive for each and every day.”
“Lori’s considerable industry experience and contributions to Dune Medical to date give us great confidence that she will successfully lead the company as we continue to bring our technology platform to bear in oncology markets,” chairman Amos Goren said in a statement. Read more